Loading...

AGEN AGENUS INC Company Mergers 8-K Filing

GNS

GN

AGENUS INC

(AGEN)

2025 8-K

Management Change

Financial Results Announced

Financial Results Announced

Asset Sale Completed

Management Changes

Amendment Agreement

Financial Results Announced

Promissory Note Agreement

Asset Acquisition Update

Divestment of Assets

Financial Statements

Financial Results

Agreement Termination

Cost Reduction Plan

Financial Results

Director Resignation

Financial Results and Direc...

Termination of Agreement

Appointment of Dr. Jennifer...

Annual Meeting of Stockholders

Completion of Asset Sale

Financial Results Announcement

Reverse Stock Split

Financial Results Announcement

Reverse Stock Split

Financial Results Announcement

Restructuring and Reorganis...

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Stock Dividend Declaration

Financial Results Announcement

External Links:

Agenus Inc. will regain full control of its LAG-3 and TIM-3 immuno-oncology programs after Incyte Corporation terminated their licensing agreement effective February 4, 2026.

AI Assistant

AGENUS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.